SEC Tracker
Get the app

Gilead Sciences GILD

Daniel Patrick O'Day (Chairman & CEO) sold 112,429 GILD at $175.16, worth $19.7M, under a 10b5-1 plan

Form
4
Filed
Importance
Routine
  1. Nov 4, 2026: 102,619 shares acquired at $72.34
  2. Nov 4, 2026: 102,619 shares sold at $175.16
  3. Nov 5, 2026: 9,810 shares acquired at $72.34
  4. Nov 5, 2026: 9,810 shares sold at $175.17

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Gilead Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Bristol Myers Squibb BMY public float $94.2B, Jun 30, 2025
  2. Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025
  3. Pfizer PFE public float $138.0B, Jun 29, 2025
  4. Amgen AMGN public float $150.1B, Jun 30, 2025
  5. Zoetis ZTS public float $69.2B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.